Pacer BioThreat Strategy ETF
VIRS
VIRS was delisted on the 10th of October, 2024.
0 hedge funds and large institutions have $0 invested in Pacer BioThreat Strategy ETF in 2024 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 4 closing their positions.
33.76% less ownership
Funds ownership: 33.76% → 0% (-34%)
100% less funds holding
Funds holding: 4 → 0 (-4)
100% less capital invested
Capital invested by funds: $1.34M → $0 (-$1.34M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$838K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$359K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$109K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$38.8K |
VIRS Hedge Fund Activity: Q4 2024 in Review
0 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q4 2024, worth a combined $0 — down 100% from $1.34M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VIRS and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Susquehanna International Group, exiting entirely with an estimated $838K sold.
- 0 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q4 2024, down from 4 in Q3 2024.
- Funds reported $0 of Pacer BioThreat Strategy ETF stock for Q4 2024, down 100% quarter-over-quarter.
- 0 funds opened new Pacer BioThreat Strategy ETF positions in Q4 2024 and 4 closed out, a net change of -4 holders.
- The largest Pacer BioThreat Strategy ETF seller in Q4 2024 was Susquehanna International Group, an estimated $838K sold.
Based on aggregated 13F filings for Q4 2024.